- Home
- JSPR vs KLRS Comparison
JSPR vs KLRS Comparison
Compare JSPR & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JSPR
- KLRS
- Stock Information
- Founded
- JSPR 2018
- KLRS 2019
- Country
- JSPR United States
- KLRS United States
- Employees
- JSPR N/A
- KLRS N/A
- Industry
- JSPR Biotechnology: Biological Products (No Diagnostic Substances)
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- JSPR Health Care
- KLRS Health Care
- Exchange
- JSPR Nasdaq
- KLRS Nasdaq
- Market Cap
- JSPR 47.6M
- KLRS 46.0M
- IPO Year
- JSPR N/A
- KLRS N/A
- Fundamental
- Price
- JSPR $2.38
- KLRS $3.71
- Analyst Decision
- JSPR Buy
- KLRS Strong Buy
- Analyst Count
- JSPR 12
- KLRS 2
- Target Price
- JSPR $30.78
- KLRS $23.00
- AVG Volume (30 Days)
- JSPR 150.8K
- KLRS 689.3K
- Earning Date
- JSPR 11-06-2025
- KLRS 11-15-2025
- Dividend Yield
- JSPR N/A
- KLRS N/A
- EPS Growth
- JSPR N/A
- KLRS N/A
- EPS
- JSPR N/A
- KLRS N/A
- Revenue
- JSPR N/A
- KLRS N/A
- Revenue This Year
- JSPR N/A
- KLRS N/A
- Revenue Next Year
- JSPR N/A
- KLRS N/A
- P/E Ratio
- JSPR N/A
- KLRS N/A
- Revenue Growth
- JSPR N/A
- KLRS N/A
- 52 Week Low
- JSPR $2.27
- KLRS $2.14
- 52 Week High
- JSPR $26.05
- KLRS $24.15
- Technical
- Relative Strength Index (RSI)
- JSPR 27.23
- KLRS 52.79
- Support Level
- JSPR $2.50
- KLRS $2.37
- Resistance Level
- JSPR $2.87
- KLRS $4.90
- Average True Range (ATR)
- JSPR 0.13
- KLRS 0.70
- MACD
- JSPR -0.01
- KLRS -0.02
- Stochastic Oscillator
- JSPR 8.96
- KLRS 24.95
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.